Showing results 1 to 20 of 35
next >
| Issue Date | Title | Author(s) |
| 2018 | Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study | Li, Jin; Xu, Ruihua; Qin, Shukui; Liu, Tianshu; Pan, Hongming; Xu, Jianming; Bi, Feng; Lim, Robert; Zhang, Suzhan; Ba, Yi; Bai, Yuxian; Fan, Nanfeng; Tsuji, Akihito; Yeh, Kun-Huei; Ma, Brigette; Wei, Vivian; Shi, Dongmei; Magherini, Emmanuelle; Shen, Lin |
| 13-May-2020 | Anticancer drug R&D landscape in China | Zhao, Shen; Zhao, Hongyun; Lv, Cheng; Gong, Jifang; Zhang, Jian; Fang, Wenfeng; Li, Jin; Hu, Xichun; Ba, Yi; Xu, Binghe; Zhang, Yanqiao; Fan, Yun; Li, Kunyan; Chen, Xiaoyuan; Yang, Zhimin; Shen, Lin; Zhang, Li |
| 2019 | Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade. | Wang, Feng; Ren, Chao; Zhao, Qi; Xu, Nong; Shen, Lin; Dai, Guanghai; Yuan, Xianglin; Chen, Ye; Yang, Shujun; Shi, Jianhua; Hu, Xichun; Lin, Xiaoyan; Zhang, Qingyuan; Feng, Jifeng; Ba, Yi; Liu, Yunpeng; Li, Wei; Shu, Yongqian; Wang, Fenghua; Xu, Rui-hua |
| Jun-2020 | Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study | Huang, Jing; Xu, Jianming; Chen, Yun; Zhuang, Wu; Zhang, Yiping; Chen, Zhendong; Chen, Jia; Zhang, Helong; Niu, Zuoxing; Fan, Qingxia; Lin, Lizhu; Gu, Kangsheng; Liu, Ying; Ba, Yi; Miao, Zhanhui; Jiang, Xiaodong; Zeng, Ming; Chen, Jianhua; Fu, Zhichao; Gan, Lu; Wang, Jun; Zhan, Xianbao; Liu, Tianshu; Li, Zhiping; Shen, Lin; Shu, Yongqian; Zhang, Tao; Yang, Qing; Zou, Jianjun |
| 2019 | Challenges in anticancer drug R&D in China | Zhao, Shen; Lv, Cheng; Gong, Jifang; Fang Wenfeng; Hu, Xichun; Ba, Yi; Chen Xiaoyuan; Yang Zhimin; Lin Shen; Li Zhang |
| 2019 | Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018) | Xu, Jianmin; Fan, Jia; Qin, Xinyu; Cai, Jianqiang; Gu, Jin; Wang, Shan; Wang, Xishan; Zhang, Suzhan; Zhang, Zhongtao; Ba, Yi; Bu, Jianhong; Cai, Jianhui; Cai, Sanjun; Zeng, Shan; Zeng, Zhaochong; Chen, Gong; Chen, Yu; Chen, Zihua; Chen, Zongyou; Cheng, Jiemin; Chi, Pan; Dai, Guanghai; Dai, Yong; Deng, Yanhong; Ding, Kefeng; Fang, Xuedong; Fu, Chuangang; Gong, Jianping; Hao, Chunyi; He, Yulong; Huang, Zhongcheng; Ji, Jiafu; Jia, Baoqing; Jiang, Kewei; Jin, Jing; Kong, Dalu; Lan, Ping; Li, Dechuan; Li, Guoli; Li, Jin; Li, Leping; Li, Yunfeng; Li, Zhixia; Liang, Houjie; Liang, Xiaobo; Lin, Feng; Lin, Jianjiang; Liu, Hongjun; Liu, Tianshu; Liu, Yunpeng; Pan, Hongming; Pan, Zhizhong; Pei, Haiping; Peng, Tao; Ren, Li; Shen, Lin; Song, Chun; Song, Tianqiang; Su, Xiangqian; Sun, Yihong; Tao, Min; Tian, Liguo; Wan, Desen; Wang, Jianping; Wang, Guiying; Wang, Guiyu; Wang, Haijiang; Wang, Jianhua; Wang, Lei; Wang, Xin; Wang, Yajie; Wang, Yi; Wang, Ziqiang; Wei, Ye; Wei, Dong; Xia, Feng; Xia, Jianguo; Xia, Lijian; Xing, Baocai; Xiong, Bin; Xu, Jianming; Xu, Nong; Xu, Ruihua; Xu, Ye; Xu, Zekuan; Xu, Zhongfa; Yang, Shujun; Yao, Hongwei; Ye, Yingjiang; Yu, Peiwu; Yuan, Ying; Zhang, Jun; Zhang, Keliang; Zhang, Wei; Zhang, Xiaotian; Zhang, Yanqiao; Zhang, Youcheng; Zhang, Zhen; Zhao, Qingchuan; Zhao, Ren; Zheng, Shu; Zhou, Aiping; Zhou, Jian; Zhou, Zongguang |
| 2013 | The Chinese subgroup from a randomized phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone as second-line treatment of HER2-amplified advanced gastric cancer (AGC) in Asian countries | Sun, Guo-ping; Sun, Yan; Xu, Rui-hua; Xu, Jian-Ming; Li, Jin; Wang, Jin-Wan; Qin, Shukui; Feng, Ji Feng; Ba, Yi; Shen, Lin; Bai, Yu-Xian; Sun, Yihong; Pan, Hongming; Cheng, Ying; Yu, Shiying; Zhong, Haijun; Bai, Li; Luo, Rongcheng; Kobayashi, Mikiro; Ohtsu, Atsushi |
| 20-May-2020 | Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors. | Ren, Chao; Wei, Xiao-Li; Xu, Nong; Shen, Lin; Dai, Guanghai; Yuan, Xianglin; Chen, Ye; Yang, Shujun; Shi, Jianhua; Hu, Xichun; Lin, Xiaoyan; Zhang, Qingyuan; Feng, Jifeng; Ba, Yi; Liu, Yunpeng; Liu, Wei; Shu, Yongqian; Xu, Rui-hua; Junshi, Shanghai |
| 2018 | Determinants and nutritional assessment value of hand grip strength in patients hospitalized with cancer | Hu, Chun-lei; Yu, Miao; Yuan, Kai-tao; Yu, Hong-lan; Shi, Ying-ying; Yang, Jia-jun; Li, Wei; Jiang, Hai-ping; Li, Zeng-ning; Xu, Hong-xia; Ba, Yi; Wang, Kun-hua; Li, Su-yi; Shi, Han-ping |
| May-2021 | Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma | Liu, Dan; Ma, Chunguang; Lu, Ping; Gong, Jifang; Ye, Dingwei; Wang, Siyang; Peng, Peijian; Bai, Yuxian; Song, Yuqin; Chen, Jianhua; Jiang, Ou; Zhang, Guojun; Ba, Yi; Chen, Li; Pan, Jianji; Li, Qi; Zhang, Liling; Gu, Shanzhi; Yin, Xianli; Cao, Bangwei; Han, Weiqing; Dong, Haiying; Guo, Jianming; Zhang, Huilai; Su, Hang; Jiang, Yongsheng; Ouyang, Weiwei; Ma, Lulin; Sun, Yan; Zhang, Feng; Lv, Jun; Guo, Yabing; Xu, Chongyuan; Qi, Junyuan; Wang, Li; Wang, Xiang; Liu, Zhen; Shen, Lin |
| Oct-2021 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study | Peng, Zhi; Liu, Tianshu; Wei, Jia; Wang, Airong; He, Yifu; Yang, Liuzhong; Zhang, Xizhi; Fan, Nanfeng; Luo, Suxia; Li, Zhen; Gu, Kangsheng; Lu, Jianwei; Xu, Jianming; Fan, Qingxia; Xu, Ruihua; Zhang, Liangming; Li, Enxiao; Sun, Yuping; Yu, Guohua; Bai, Chunmei; Liu, Yong; Zeng, Jiangzheng; Ying, Jieer; Liang, Xinjun; Xu, Nong; Gao, Chao; Shu, Yongqian; Ma, Dong; Dai, Guanghai; Li, Shengmian; Deng, Ting; Cui, Yuehong; Fang, Jianmin; Ba, Yi; Shen, Lin |
| 2016 | Expert consensus on maintenance treatment for metastatic colorectal cancer in China | Xu, Rui-Hua; Shen, Lin; Li, Jin; Xu, Jian-Ming; Bi, Feng; Ba, Yi; Bai, Li; Shu, Yong-Qian; Liu, Tian-Shu; Li, Yu-Hong; Bai, Chun-Mei; Yuan, Xiang-Lin; Zhang, Jun; Chen, Gong; Zhou, Ai-Ping; Yuan, Ying; Wang, Xi-Jing; Qian, Xiao-Ping; Deng, Yan-Hong |
| 2019 | Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition) | Li, Jian; Yuan, Ying; Yang, Fan; Wang, Yi; Zhu, Xu; Wang, Zhenghang; Zheng, Shu; Wan, Desen; He, Jie; Wang, Jianping; Ba, Yi; Bai, Chunmei; Bai, Li; Bai, Wei; Bi, Feng; Cai, Kaican; Cai, Muyan; Cai, Sanjun; Chen, Gong; Chen, Keneng; Chen, Lin; Chen, Pengju; Chi, Pan; Dai, Guanghai; Deng, Yanhong; Ding, Kefeng; Fan, Qingxia; Fang, Weijia; Fang, Xuedong; Feng, Fengyi; Fu, Chuangang; Fu, Qihan; Gu, Yanhong; He, Yulong; Jia, Baoqing; Jiang, Kewei; Lai, Maode; Lan, Ping; Li, Enxiao; Li, Dechuan; Li, Jin; Li, Leping; Li, Ming; Li, Shaolei; Li, Yexiong; Li, Yongheng; Li, Zhongwu; Liang, Xiaobo; Liang, Zhiyong; Lin, Feng; Lin, Guole; Liu, Hongjun; Liu, Jianzhong; Liu, Tianshu; Liu, Yunpeng; Pan, Hongming; Pan, Zhizhong; Pei, Haiping; Qiu, Meng; Qu, Xiujuan; Ren, Li; Shen, Zhanlong; Sheng, Weiqi; Song, Chun; Song, Lijie; Sun, Jianguo; Sun, Lingyu; Sun, Yingshi; Tang, Yuan; Tao, Min; Wang, Chang; Wang, Haijiang; Wang, Jun; Wang, Shubin; Wang, Xicheng; Wang, Xishan; Wang, Ziqiang; Wu, Aiwen; Wu, Nan; Xia, Lijian; Xiao, Yi; Xing, Baocai; Xiong, Bin; Xu, Jianmin; Xu, Jianming; Xu, Nong; Xu, Ruihua; Xu, Zhongfa; Yang, Yue; Yao, Hongwei; Ye, Yingjiang; Yu, Yonghua; Yu, Yueming; Yue, Jinbo; Zhang, Jingdong; Zhang, Jun; Zhang, Suzhan; Zhang, Wei; Zhang, Yanqiao; Zhang, Zhen; Zhang, Zhongtao; Zhao, Lin; Zhao, Ren; Zhou, Fuxiang; Zhou, Jian; Jin, Jing; Gu, Jin; Shen, Lin |
| 2017 | Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial | Xu, Rui-Hua; Shen, Lin; Wang, Ke-Ming; Wu, Gang; Shi, Chun-Mei; Ding, Ke-Feng; Lin, Li-Zhu; Wang, Jin-Wan; Xiong, Jian-Ping; Wu, Chang-Ping; Li, Jin; Liu, Yun-Peng; Wang, Dong; Ba, Yi; Feng, Jue-Ping; Bai, Yu-Xian; Bi, Jing-Wang; Ma, Li-Wen; Lei, Jian; Yang, Qing; Yu, Hao |
| Jul-2021 | First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis. | Shen, Lin; Bai, Yuxian; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, Hongming; Bai, Chunmei; Bai, Li; Cheng, Ying; Zhang, Jingdong; Zhong, Haijun; Ba, Yi; Hu, Wenwei; Xu, Ruihua; Guo, Weijian; Qin, Shukui; Yang, Nong; Lu, Jianwei; Shitara, Kohei; Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian; Liu, Tianshu |
| Oct-2022 | First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis | Liu, Tianshu; Bai, Yuxian; Lin, Xiaoyan; Li, Wei; Wang, Jufeng; Zhang, Xiaochun; Pan, Hongming; Bai, Chunmei; Bai, Li; Cheng, Ying; Zhang, Jingdong; Zhong, Haijun; Ba, Yi; Hu, Wenwei; Xu, Ruihua; Guo, Weijian; Qin, Shukui; Yang, Nong; Lu, Jianwei; Shitara, Kohei; Lei, Ming; Li, Mingshun; Bao, Nicole; Chen, Tian; Shen, Lin |
| Aug-2020 | National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version) | Sun, Yan; Zheng, Shu; Wan, Desen; Gu, Jin; Wang, Jianping; Zhang, Suzhan; Cai, Sanjun; Fang, Xuedong; Fu, Chuangang; Jia, Baoqing; Kong, Dalu; Lan, Ping; Pan, Zhizhong; Pei, Haiping; Qiu, Huizhong; Song, Chun; Wang, Guiying; Wang, Xishan; Wang, Ziqiang; Xu, Jianmin; Xu, Zhongfa; Yan, Jin; Ye, Yingjiang; Yu, Yueming; Zhang, Zhongtao; Zhao, Ren; Lian, Lei; Liu, Qian; Peng, Yifan; Shen, Lin; Xu, Ruihua; Li, Jin; Ba, Yi; Bai, Chunmei; Bai, Li; Deng, Yanhong; Li, Jian; Liu, Tianshu; Liu, Yunpeng; Pan, Hongming; Tao, Min; Xu, Jianming; Yuan, Xianglin; Yuan, Ying; Zhang, Yanqiao; Zhou, Aiping; Wang, Feng; Wang, Xicheng; Li, Yexiong; Zhang, Zhen; Cai, Yong; Gao, Yuanhong; Jin, Jing; Li, Yongheng; Liu, Shixin; Wang, Renben; Wu, Junxin; Zhang, Hongyan; Zhu, Li; Zhu, Yuan; Tang, Yuan; Liang, Zhiyong; Jin, Mulan; Liang, Li; Qiu, Zhiqiang; Sheng, Weiqi; Sun, Baocun; Xue, Weicheng; Zhou, Weixun; Sun, Yingshi; Dong, Jiangning; Wang, Yi; Yu, Tao; Zhang, Xiaoyan; Zhou, Zhiyang; Sun, Ruijia; Wang, Juan; Sun, Ruijia; Tang, Yuan; Wang, Feng; Wang, Juan; Zhou, Weixun; Yang, Yong; Chen, Jiajia; Chen, Yongkang; Cheng, Yu; Han, Zihan; Huang, An; Huang, Dandan; Li, Xin; Li, Yukun; Shi, Jingyi; Shi, Mengyuan; Song, Can; Wang, Hanyang; Xu, Jingxuan |
| Jul-2021 | Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors | Xu, Yingying; Wang, Yakun; Gong, Jifang; Zhang, Xiaotian; Peng, Zhi; Sheng, Xinan; Mao, Chenyu; Fan, Qingxia; Bai, Yuxian; Ba, Yi; Jiang, Da; Yang, Fen; Qi, Changsong; Li, Jian; Wang, Xicheng; Zhou, Jun; Lu, Ming; Cao, Yanshuo; Yuan, Jiajia; Liu, Dan; Wang, Zhenghang; Fang, Jianmin; Shen, Lin |
| 2023 | Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer | Bai, Ming; Lu, Yao; Shi, Chunmei; Yang, Jianwei; Li, Wei; Yin, Xianli; Huang, Chenghui; Shen, Lin; Xie, Liangzhi; Ba, Yi |
| 20-May-2020 | A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor. | Gong, Jifang; Deng, Ting; Li, Jie; Lu, Ming; Li, Jian; Ba, Yi; Yu, Qiuqiong; Shen, Lin |
